CAS 1223405-08-0

1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)-, sulfate (1:1)

CAS : 1223405-08-0

Formule : C₂₁H₂₄F₂N₆O₆S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 526.5137

Ref: IN-DA00174F

Larotrectinib sulfate

CAS : 1223405-08-0

Larotrectinib sulfate

Degré de pureté : ≥98%

Masse moléculaire : 526.51g/mol

Ref: 54-BUP13049

Larotrectinib sulfate

CAS : 1223405-08-0

Larotrectinib sulfate (LOXO-101 sulfate) is an oral active and specific ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).

Formule : C₂₁H₂₂F₂N₆O₂·H₂O₄S

Degré de pureté : 98.62% - 99.76%

Couleur et forme : Solid

Masse moléculaire : 526.51

Ref: TM-T6880

Larotrectinib Sulfate

Produit contrôlé

CAS : 1223405-08-0

Applications Larotrectinib Sulfate is a potent and selective oral ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).
References Anon.: Cancer Discovery, 6, 4 (2016); Passiglia, F., et al.: Expert Opin. Investig. Drugs, 25, 385 (2016)

Formule : C₂₁H₂₂F₂N₆O₂·(H₂O₄S)

Couleur et forme : Neat

Masse moléculaire : 428.44 + (98.08)

Ref: TR-L175933

Larotrectinib sulphate

CAS : 1223405-08-0

A potent ATP-competitive inhibitor of tropomyosin-related kinases (TRK1, TRK2 and TRK3), members of the receptor tyrosine kinase family of neurotrophin receptors. Tumors with oncogenic TRK fusions are sensitive to larotrectinib, leading to reduced proliferation and tumor growth in patients with soft tissue sarcoma, triple-negative breast cancer and lung cancer.

Formule : C₂₁H₂₂F₂N₆O₂H₂SO₄

Degré de pureté : Min. 95%

Masse moléculaire : 526.51 g/mol

Ref: 3D-BL161518